



IPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: FISHMAN=11A

|                            |   |                        |
|----------------------------|---|------------------------|
| In re Application of:      | ) | Art Unit: 1651         |
|                            | ) |                        |
| Pnina FISHMAN              | ) | Examiner:              |
|                            | ) |                        |
| Appln. No.: 10/715,823     | ) | Washington, D.C.       |
|                            | ) |                        |
| Filed: November 19, 2003   | ) | May 12, 2004           |
|                            | ) |                        |
| For: A3AR AGONISTS FOR THE | ) | Confirmation No.: 3649 |
| TREATMENT OF INFLAMMATORY  | ) |                        |
| ARTHRITIS                  | ) |                        |

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner of Patents and Trademarks  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed before the mailing date of a first office action on the merits.

[X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form PTO/SB/08A) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached.

[X] Document BA is U.S. patent and/or published application. As this is a U.S. application filed after June 30, 2003, or an entry into national stage under 35 USC §371 after June 30, 2003, the requirement to file copies of such U.S. patents or published applications has been waived. (Office of Patent Legal Administration - Pre O.G. Notice of July 11, 2003).


[X] 3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20). However, a concise explanation of relevance is being provided in the form of the attached International Search Report.

4. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK  
Attorneys for Applicant

By:

  
Sheridan Neimark  
Reg. No. 20,520

624 Ninth Street, N.W., Suite 300  
Washington, D.C. 20001-5303  
Telephone: (202) 628-5197  
Facsimile: (202) 737-3528  
:jaa  
G:\BN\C\cohn\FISHMAN11A\pto\IDS 12May04.doc

A circular black ink stamp from the Intellectual Property Office (IPO). The text "IPO" is at the top, "MAY 12 2004" is in the center, and "PATENT & TRADEMARK OFFICE" is at the bottom.[illegible][illegible]

|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |      |                          |               |
|---|------|--------------------------|---------------|
| Substitute for form 1449A/PTO   |      | <b>Complete if Known</b> |               |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |      | Application Number       | 10/715,823    |
|   |      | Filing Date              | 11-19-2003    |
|   |      | First Named Inventor     | Prina FISHMAN |
|   |      | Group Art Unit           |               |
|   |      | Examiner Name            |               |
| Sheet 2   | of 2 | Attorney Docket Number   | FISHMAN=11A   |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|---|-----------------------|--|----------------|
| Examiner Initials*                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published                   | T <sup>2</sup> |
|   | BB                    | BAHARAV, Ehud, et al, "The Anti-Inflammatory Effect of A3 Adenosine Receptor Agonists in Murine Autoimmune Arthritis Models", International Journal of Molecular Medicine, v. 12, n. Supplement 1, pp. S42 (2003).   |                |
|   | BC                    | BAHARAV, Ehud, et al, "The Effect of Adenosine and the A3 Adenosine Receptor Agonist IB-MECA on Joint Inflammation and Autoimmune Diseases Models", International Journal of Molecular Medicine, v. 10, n. Supplement 1, pp. S104 (2002).                                    |                |
|   | BD                    | FANG, G., et al, "Adenosine (ADO) Agonists Protect Mice from Death in a Model of Endotoxemia by Binding to A <sub>2A</sub> but not A <sub>3</sub> ADO Receptors", Abstracts of the Interscience Conference on AntiMicrobial Agents and Chemotherapy, v. 41, pp. 754, (2001), |                |
|   | BE                    | HASKO, G., et al, "Stimulation of Adenosine 3 Receptors Exerts Anti-Inflammatory Effects in Acute and Chronic Models of Inflammation", Drug Development Research, v. 43, n.1, pp. 39, (January 1998).  |                |
|   | BF                    | MABLEY, Jon, et al, "The A3 Adenosine Agonist, IB-MECA, Protects Against the Development of Arthritis and Reverses Established Arthritis", FASEB Journal, vol. 16, n. 5, pp. A1044, (22 March 2002).   |                |
|   | BG                    | SZABO, Csaba, et al, "Suppression of Macrophage Inflammatory Protein (MIP)-1 $\alpha$ Production and Collagen-Induced Arthritis by Adenosine Receptor Agonists", British Journal of Pharmacology, v. 125, pp.379-387, (1998).  |                |
|   |                       |  |                |
|   |                       |  |                |
|   |                       |  |                |
|   |                       |  |                |
|   |                       |  |                |
|   |                       |  |                |
|   |                       |  |                |
|   |                       |  |                |
|   |                       |  |                |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.